Publications

Landmark publications:

Year 2013

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial

Prof Jayant S Vaidya PhD, Prof Frederik Wenz MD, Prof Max Bulsara PhD, Prof Jeffrey S Tobias FRCR, Prof David J Joseph FRACR, Prof Mohammed Keshtgar PhD, Henrik L Flyger MD, Samuele Massarut MD, Michael Alvarado MD, Prof Christobel Saunders FRACS, Prof Wolfgang Eiermann MD, Marinos Metaxas PhD, Elena Sperk MD, Prof Marc Sütterlin MD, Douglas Brown FRCS, Prof Laura Esserman MD, Mario Roncadin MD, Prof Alastair Thompson FRCS, Prof John A Dewar FRCR, Helle M R Holtveg MD, Steffi Pigorsch MD, Mary Falzon FRCPath, Eleanor Harris MD, April Matthews BSc, Chris Brew-Graves MSc, Ingrid Potyka PhD, Tammy Corica BSc, Norman R Williams PhD, Prof Michael Baum MD, on behalf of the TARGIT trialists' group

The Lancet, Early Online Publication, 11 November 2013

doi:10.1016/S0140-6736(13)61950-9


Year 2010

Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.

Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M.

Lancet. 2010 Jul 10;376(9735):91-102.


Year 2005

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group.

Lancet. 2005 Jan 1-7;365(9453):60-2.